Latest news with #BioVie
Miami Herald
16-05-2025
- Business
- Miami Herald
BioVie and Liberty Star Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FLORIDA / ACCESS Newswire / May 16, 2025 / RedChip Companies will air interviews with BioVie Inc. (NASDAQ:BIVI) and Liberty Star Minerals (OTCQB:LBSR) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this Saturday, May 17, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S. Access the interviews in their entirety at: BIVI: In an exclusive interview, Cuong Do, President and CEO of BioVie, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to share how BioVie is unlocking the science of longevity through novel therapeutics targeting neurodegenerative diseases and advanced liver conditions. Do highlights the Company's lead drug candidate, bezisterim, a first-in-class small molecule designed to combat chronic inflammation and insulin resistance-key drivers in Alzheimer's and Parkinson's disease, as well as Long COVID. He also discusses BIV201, BioVie's Orphan-designated liver therapy being developed to treat - and may become the first approved treatment - for ascites, an end-stage liver disease condition of 50%+ mortality rate in 12 months. With multiple clinical programs advancing across Phase 2 and Phase 3 trials and a clear path toward commercialization, BioVie is positioned at the forefront of transformative healthcare innovation. Pete O'Heeron, Chairman of Liberty Star, and Liberty Star board member Gerardo King, appear on the RedChip Small Stocks Big Money™ show on Bloomberg TV to highlight the Company's dual-track strategy targeting high-grade gold and large-scale copper-gold mineralization in Arizona. They discuss recent bonanza-grade assay results from the Red Rock Canyon Gold Project, where surface samples have returned values as high as 107.5 g/t gold, and the validation of a porphyry copper system at the Hay Mountain Project through Liberty Star's 2024 drill campaign. With gold prices near all-time highs and copper demand surging amid global electrification, Liberty Star is actively pursuing a joint venture to accelerate project development while minimizing shareholder dilution. The company's experienced leadership and strategic positioning in one of North America's most prolific mining regions underscore its potential to unlock significant value through near- and long-term exploration success. BIVI and LBSR are clients of RedChip Companies. Please read our full disclosure at About BioVie Inc. BioVie Inc. (NASDAQ:BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders (Long COVID, Alzheimer's disease and Parkinson's disease) and advanced liver disease. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-kB, and the associated neuroinflammation and insulin resistance but not ERK and NFkB homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of AD and PD. Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of Long COVID. In liver disease, the Company's Orphan drug candidate BIV201 (continuous infusion terlipressin), with FDA Fast Track status, is being evaluated and discussed with guidance received from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the reduction of further decompensation in participants with liver cirrhosis and ascites. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For more information, visit About Liberty Star Liberty Star Uranium & Metals Corp. (LBSR:OTCQB), d/b/a Liberty Star Minerals, is an Arizona-based mineral exploration company engaged in the acquisition, exploration, and development of mineral properties in Arizona and the southwest USA. Currently the company controls properties that are located over what management considers some of North America's richest mineralized regions for copper, gold, silver, molybdenum (moly), and associated metals. The Company's premiere property is the Hay Mountain property (exploration stage) for porphyry copper, gold, moly and other commercially important minerals. Specific targets have been selected to explore for near-surface and deep-seated ore bodies, of which there are numerous analogs nearby. Contiguous with the primary Hay Mountain porphyry exploration target, and part of the overall Hay Mountain property, is an increasingly attractive area of exploration stage gold mineralization denominated Red Rock Canyon. Red Rock Canyon exhibits what we believe are extensive, promising hydrothermal associated gold-bearing structures that are documented in historical public and Company records. View numerous geoscientific reports on our website. The Hay Mountain & Red Rock Canyon properties are in Cochise County (southeast) Arizona, USA. Follow Liberty Star Minerals on Facebook, LinkedIn & [X]Twitter About RedChip Companies RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 33 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. To learn more about RedChip's products and services, please visit: "Discovering Tomorrow's Blue Chips Today"™ Follow RedChip on LinkedIn: Follow RedChip on Facebook: Follow RedChip on Instagram: Follow RedChip on Twitter: Follow RedChip on YouTube: Follow RedChip on Rumble: Subscribe to our Mailing List: Contact: Dave GentryRedChip Companies Inc.1-407-644-4256info@ --END-- SOURCE: RedChip Companies, Inc.
Yahoo
16-05-2025
- Business
- Yahoo
BioVie and Liberty Star Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FLORIDA / / May 16, 2025 / RedChip Companies will air interviews with BioVie Inc. (NASDAQ:BIVI) and Liberty Star Minerals (OTCQB:LBSR) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this Saturday, May 17, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S. Access the interviews in their entirety at: BIVI: LBSR: In an exclusive interview, Cuong Do, President and CEO of BioVie, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to share how BioVie is unlocking the science of longevity through novel therapeutics targeting neurodegenerative diseases and advanced liver conditions. Do highlights the Company's lead drug candidate, bezisterim, a first-in-class small molecule designed to combat chronic inflammation and insulin resistance-key drivers in Alzheimer's and Parkinson's disease, as well as Long COVID. He also discusses BIV201, BioVie's Orphan-designated liver therapy being developed to treat - and may become the first approved treatment - for ascites, an end-stage liver disease condition of 50%+ mortality rate in 12 months. With multiple clinical programs advancing across Phase 2 and Phase 3 trials and a clear path toward commercialization, BioVie is positioned at the forefront of transformative healthcare innovation. Pete O'Heeron, Chairman of Liberty Star, and Liberty Star board member Gerardo King, appear on the RedChip Small Stocks Big Money™ show on Bloomberg TV to highlight the Company's dual-track strategy targeting high-grade gold and large-scale copper-gold mineralization in Arizona. They discuss recent bonanza-grade assay results from the Red Rock Canyon Gold Project, where surface samples have returned values as high as 107.5 g/t gold, and the validation of a porphyry copper system at the Hay Mountain Project through Liberty Star's 2024 drill campaign. With gold prices near all-time highs and copper demand surging amid global electrification, Liberty Star is actively pursuing a joint venture to accelerate project development while minimizing shareholder dilution. The company's experienced leadership and strategic positioning in one of North America's most prolific mining regions underscore its potential to unlock significant value through near- and long-term exploration success. BIVI and LBSR are clients of RedChip Companies. Please read our full disclosure at About BioVie Inc. BioVie Inc. (NASDAQ:BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders (Long COVID, Alzheimer's disease and Parkinson's disease) and advanced liver disease. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-kB, and the associated neuroinflammation and insulin resistance but not ERK and NFkB homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of AD and PD. Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of Long COVID. In liver disease, the Company's Orphan drug candidate BIV201 (continuous infusion terlipressin), with FDA Fast Track status, is being evaluated and discussed with guidance received from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the reduction of further decompensation in participants with liver cirrhosis and ascites. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For more information, visit About Liberty Star Liberty Star Uranium & Metals Corp. (LBSR:OTCQB), d/b/a Liberty Star Minerals, is an Arizona-based mineral exploration company engaged in the acquisition, exploration, and development of mineral properties in Arizona and the southwest USA. Currently the company controls properties that are located over what management considers some of North America's richest mineralized regions for copper, gold, silver, molybdenum (moly), and associated metals. The Company's premiere property is the Hay Mountain property (exploration stage) for porphyry copper, gold, moly and other commercially important minerals. Specific targets have been selected to explore for near-surface and deep-seated ore bodies, of which there are numerous analogs nearby. Contiguous with the primary Hay Mountain porphyry exploration target, and part of the overall Hay Mountain property, is an increasingly attractive area of exploration stage gold mineralization denominated Red Rock Canyon. Red Rock Canyon exhibits what we believe are extensive, promising hydrothermal associated gold-bearing structures that are documented in historical public and Company records. View numerous geoscientific reports on our website. The Hay Mountain & Red Rock Canyon properties are in Cochise County (southeast) Arizona, USA. Follow Liberty Star Minerals on Facebook, LinkedIn & [X]Twitter About RedChip Companies RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 33 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. To learn more about RedChip's products and services, please visit: "Discovering Tomorrow's Blue Chips Today"™ Follow RedChip on LinkedIn: Follow RedChip on Facebook: Follow RedChip on Instagram: Follow RedChip on Twitter: Follow RedChip on YouTube: Follow RedChip on Rumble: Subscribe to our Mailing List: Contact: Dave GentryRedChip Companies Inc.1-407-644-4256info@ --END-- SOURCE: RedChip Companies, Inc. View the original press release on ACCESS Newswire
Yahoo
14-05-2025
- Health
- Yahoo
BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease on May 28, 2025
CARSON CITY, Nev., May 14, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), ('BioVie' or the 'Company'), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that it will host a virtual key opinion leader (KOL) event featuring Suzanne de la Monte, MD, MPH (Brown University Warren Alpert Medical School, Providence VA Medical Center) and Mark Stacy, MD (Medical University of South Carolina College of Medicine), who will join company management to discuss the unmet need and current treatment landscape for Parkinson's disease on Wednesday, May 28, 2025 at 12:00 PM ET. To register, click here. The event will provide an update on BioVie's Phase 2 trial (SUNRISE-PD; evaluating bezisterim (NE3107) for the treatment of Parkinson's disease. Bezisterim is a novel, orally-administered small molecule that has been shown to reverse insulin resistance and selectively inhibit inflammation-driven ERK- and NF-κB-stimulated inflammatory mediators without inhibiting their homeostatic functions. Inflammation and the associated insulin resistance are important to the presentation of Parkinson's symptoms. BioVie is currently enrolling patients recently diagnosed with Parkinson's disease who have not yet begun treatment in order to measure bezisterim's potential impact on clinical signs and effects on biomarkers that may correlate with disease-modification for the SUNRISE-PD trial. A live question and answer session will follow the formal presentations. About Suzanne de la Monte, MD, MPHSuzanne de la Monte, MD, MPH is Professor in Pathology and Laboratory Medicine, Neurology, & Neurosurgery at the Warren Alpert Medical School of Brown University and Chief of Pathology & Laboratory Medicine at the Providence VA Medical Center. Dr. de la Monte is also a medical staff member at the Rhode Island Hospital and Women and Infants Hospital of Rhode Island and formerly a research fellow at the National Institutes of Health. She received residency training in Anatomic and Pediatric Pathology at Johns Hopkins and fellowship training in Neuropathology at the Massachusetts General Hospital (MGH). Dr. de la Monte leads programs in basic, translational, and clinical research on mechanisms and the neurological consequences of brain insulin resistance and metabolic dysfunction, and coined the term 'Type 3 Diabetes' which refers to the hypothesis that insulin resistance in the brain causes neurodegenerative disorders. She has over 300 peer-reviewed articles published. About Mark Stacy, MDMark Stacy, MD is a Professor in the College of Medicine at Medical University of South Carolina. He received his MD from the University of Missouri, Columbia, Missouri, and completed his residency training at Hahnemann (Drexel) University. Dr. Stacy also has a fellowship in Movement Disorders at Baylor College of Medicine. His prior positions include assistant professor at University of Missouri, Director of the Muhammad Ali Parkinson Research Center at the Barrow Neurological Institute in Phoenix, Arizona, and Director and subsequently Vice Dean of Parkinson Disease and Movement Disorders at Duke University. Dr. Stacy also completed a sabbatical in the Human Motor Control Section at the National Institutes of Health and served as Dean of Brody School of Medicine and Vice Chancellor of the Division of Health Sciences at East Carolina University from 2017 – 2021. He has published more than 300 journal articles and book chapters on the topics of clinical and neurobiological aspects, complications, and treatment options in Parkinson Disease; dystonia; Tourette's syndrome; and movement disorders. About Parkinson's Disease Parkinson's disease (PD) is a progressive neurodegenerative disorder that primarily affects movement. It is characterized by the loss of dopamine-producing neurons in the substantia nigra, a region of the brain critical for motor control. Core symptoms include tremors, muscle rigidity, bradykinesia (slowness of movement), postural instability, and difficulties with speech.1-2 Non-motor symptoms, such as cognitive impairment, mood disorders, and autonomic dysfunction, also significantly impact patients' quality of life.3 In the early stages, symptoms are often mild and may include subtle tremors, slight movement difficulties, and changes in handwriting or facial expressions. As the disease progresses, motor symptoms become more pronounced, leading to difficulties with balance, speech, and daily activities, often requiring full-time care in later stages.4 Since the 1960s, when dopamine's critical role in Parkinson's disease was first identified, levodopa has remained the cornerstone of treatment, providing significant symptom relief by replenishing dopamine levels in the brain.5-6 However, long-term use is associated with complications such as motor fluctuations—where symptom control becomes less stable—and dyskinesia, involuntary movements that can become debilitating.7-9 Emerging research highlights the role of chronic inflammation and insulin resistance in the onset and progression of Parkinson's disease. Neuroinflammation, driven by activated microglia and elevated levels of pro-inflammatory cytokines, contributes to oxidative stress and accelerates neuronal degeneration.10-12 Additionally, insulin resistance, which impairs the brain's ability to regulate glucose metabolism, has been linked to increased neurodegeneration and worsening motor symptoms.13-14 These metabolic dysfunctions create a harmful cycle that exacerbates disease progression, underscoring the potential of anti-inflammatory and insulin-sensitizing therapies as new avenues for treatment. About Bezisterim Bezisterim (NE3107) is an orally bioavailable, blood-brain barrier (BBB)-permeable modulator of inflammation and insulin-sensitizer. In addition, it is not immunosuppressive and has a low risk of drug-drug interaction. By binding to ERK and selectively modulating NFκB activation and TNF-α production, BioVie believes that bezisterim may offer clinical improvements in several disease indications, including Alzheimer's disease, Parkinson's disease and long COVID. In Parkinson's disease, BioVie is currently enrolling patients in the Phase 2 SUNRISE-PD clinical trial evaluating the safety and efficacy of bezisterim on motor and non-motor symptoms in patients who have not been treated with carbidopa/levodopa, with topline data expected in late 2025 or early 2026. A previous Phase 2 study of bezisterim in Parkinson's disease (NCT05083260) completed in 2022, and data presented at the AD/PD™ 2023 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders in Gothenburg, Sweden in March 2023 showed significant improvements in 'morning on' symptoms and clinically meaningful improvement in motor control in patients treated with a combination of bezisterim and levodopa versus patients treated with levodopa alone, and no drug-related adverse events. In long COVID, bezisterim has the potential to reduce neurological symptoms including fatigue and cognitive dysfunction. Persistently circulating viral spike proteins are believed to trigger TLR-4 driven activation of NFκB and the subsequent expression of inflammatory cytokines (IL-6, TNF, IFNg). BioVIe's Phase 2 ADDRESS-LC study, is a randomized (1:1), placebo-controlled, multicenter trial in approximately 200 patients to evaluate the safety, tolerability and potential efficacy of 3 months of treatment with bezisterim to reduce the neurocognitive symptoms associated with long COVID, including difficulty concentrating or remembering things ('brain fog') and fatigue. In Alzheimer's disease, BioVie conducted and reported efficacy data on its Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate bezisterim in patients who have mild-to-moderate Alzheimer's disease (NCT04669028) in 2023. Results of a Phase 2 investigator-initiated trial (NCT05227820) showing bezisterim-treated patients experienced improved cognition and biomarker levels were presented at the Clinical Trials on Alzheimer's Disease (CTAD) annual conference in December 2022. An estimated six million Americans suffer from Alzheimer's disease. About BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders (Long COVID, Alzheimer's disease and Parkinson's disease) and advanced liver disease. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-kB, and the associated neuroinflammation and insulin resistance but not ERK and NFkB homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of AD and PD. Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of Long COVID. In liver disease, the Company's Orphan drug candidate BIV201 (continuous infusion terlipressin), with FDA Fast Track status, is being evaluated and discussed with guidance received from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the reduction of further decompensation in participants with liver cirrhosis and ascites. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For more information, visit . References 1 Cleveland Clinic. Parkinson's Disease. Last reviewed: 2022 Apr 15.2 Jankovic J. J Neurol Neurosurg Psychiatry. 2008;79(4):368-376.3 Postuma RB, Berg D, Stern M, et al. Mov Disord. 2015;30(12):1591-1601.4 Kalia LV and Lang AE. Lancet. 2015;386(9996):896-912.5 Hornykiewicz O. Angew Chem Int Ed. 2002;41(17):2934-2941.6 Olanow CW, Obeso JA and Stocchi F. Lancet Neurol. 2006;5(8):677-687.7 Ahlskog JE and Muenter MD. Mov Disord. 2001;16(3):448-458.8 Espay AJ, Morgante F, Merola A, et al. Ann Neurol. 2018;84(6):797-811.9 Cilia R and Akpalu A. J Neural Transm. 2020;127(5):889-916.10 Jurcau A, Andronie-Cioara FL, Nistor-Cseppento DC, et al. Int J Mol Sci. 2023;24:14582.11 Pajares M, Rojo AI, Manda G, et al. Cells. 2020;9:1687.12 Isik S, Kiyak BY, Akbayir R, et al. Cells. 2023;12:1012.13 Zagare A, Hemedan A, Almeida C, et al. Mov Disord. 2025;40(1):67-76.14 Ruiz-Pozo VA, Tamayo-Trujillo R, Cadena-Ullauri S, et al. Nutrients. 2023;15(16):3585. Forward-Looking StatementsThis press release contains forward-looking statements, which may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. Although BioVie Inc. believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Actual results may vary materially from those expressed or implied by the statements herein due to the Company's ability to successfully raise sufficient capital on reasonable terms or at all, available cash on hand and contractual and statutory limitations that could impair our ability to pay future dividends, our ability to complete our pre-clinical or clinical studies and to obtain approval for our product candidates, our ability to successfully defend potential future litigation, changes in local or national economic conditions as well as various additional risks, many of which are now unknown and generally out of the Company's control, and which are detailed from time to time in reports filed by the Company with the SEC, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. BioVie Inc. does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law. For Investor Relations Inquiries:Bruce MackleManaging Director, LifeSci Advisors, LLCbmackle@ For Media Relations Inquiries:Melyssa WeibleManaging Partner, Elixir Health Public Relationsmweible@ in to access your portfolio
Associated Press
25-04-2025
- Business
- Associated Press
New to The Street Airs on Bloomberg TV Saturday, April 26 at 6:30 PM ET Featuring BioVie (NASDAQ: BIVI), Skip Barber Racing School with CFO Michael Berg, CommercialVille.tv, Sustainable Green Team (OTCPK: SGTM) WaterLess Garden, and The Business of Blockchain with Michael Casey
Presented as Sponsored Programming by Bitdeer. NEW YORK CITY, NEW YORK / ACCESS Newswire / April 25, 2025 / New to The Street, the nation's longest-running business television series dedicated to emerging innovation and investor awareness, will air Episode #651 on Bloomberg Television this Saturday, April 26 at 6:30 PM ET. This episode features visionary leaders and technologies across biotech, motorsport education, blockchain, sustainable infrastructure, and small business marketing. BioVie Inc. (NASDAQ:BIVI) BioVie is pioneering treatments for Alzheimer's disease (AD), Parkinson's disease (PD), and long COVID with its lead drug candidate Bezisterim (NE3107) - a brain-penetrating, anti-inflammatory insulin sensitizer with promising clinical results in cognition and motor improvement. BioVie is also advancing BIV201, an Orphan-designated treatment for liver cirrhosis, currently progressing toward Phase 3 development under FDA Fast Track status. Skip Barber Racing School - Featuring CFO Michael Berg Michael Berg, CFO of Skip Barber Racing School, discusses the company's future and enduring legacy as the gold standard in American motorsport education. With over 45 years of history, the brand is now expanding its reach with new programs, event experiences, and content partnerships. - Featuring Spokesperson Paul Lawrence is the first-ever Zip Code Targeted, All-Video Search Engine using patented technology to provide hyper-local, advertiser-generated commercial results. It's transforming how small businesses connect with their communities. ' is perfectly positioned to help the 34 million U.S.-based small businesses harness the power of video marketing during a crucial time in our economy,' said Paul Lawrence, spokesperson for 'Small businesses employ over 61 million Americans-or nearly 47% of the private sector workforce-and is here to help.' The platform empowers business owners to upload their own commercial content and appear in zip-code-specific video galleries, making stagnant text-based listings obsolete. Sustainable Green Team (OTCPK:SGTM) SGTM introduces its WaterLess Garden™ - a low-maintenance, drought-resistant landscaping innovation built for municipalities, developers, and eco-conscious consumers. This solution eliminates the need for watering while delivering high-impact visual appeal. The Business of Blockchain - Featuring Michael Casey Featuring Michael Casey, former Chief Content Officer at CoinDesk, this segment explores how blockchain, AI, and decentralized networks are redefining global finance and commerce. Presented by Bitdeer a world leader in blockchain infrastructure and computing power, this conversation frames the road ahead for enterprise adoption and token-driven ecosystems. About New to The Street New to The Street has been broadcasting as sponsored programming since 2009, airing weekly on Bloomberg TV and Fox Business. It is now the fastest-growing digital financial media platform, with over 2.5 million YouTube subscribers, massive NYC billboard reach (NASDAQ, Reuters, and bus shelters), and strategic distribution across LinkedIn, X, Facebook, and Instagram. The show offers turnkey, multi-channel investor exposure for public and private companies, combining TV, digital, social, and outdoor into one powerful visibility platform. For full episodes and more info: Monica Brennan - Media & Partnerships [email protected] SOURCE: New To The Street press release
